UBS reiterates Cigna stock buy rating on 2026-2030 outlook
UBS reiterated a Buy rating and $400 price target for Cigna (CI), citing its 2026-2030 outlook. Cigna expects $280B revenue and $30.45 EPS by 2026, with 10-14% EPS growth through 2030. The company also reported Q2 earnings and revenue above estimates. Guggenheim raised its target to $361, while Evercore ISI initiated coverage with a $290 target.
How this was made
The 30-second read
Why it matters
The reiteration reinforces existing bullish sentiment but adds no new quantitative catalyst.
Market read
The piece is a recap of already‑public earnings and guidance, with an analyst reiteration that is unlikely to move the market.
What to watch
Potential impact of Evernorth's rebate‑free pharmacy model not yet reflected in price.
Background
UBS reiterates a Buy rating and $400 price target for Cigna, citing undervaluation and the company's long‑term outlook.
Ticker impact
The article repeats Cigna's Q2 earnings and 2026-2030 outlook that were released over two months ago, offering no new data.
likely neutral to slight downside as investors may view the repeat of old guidance as a lack of new upside.
All figures quoted (revenue, EPS, buyback expectations) were disclosed in the July 30 earnings release; the article adds no new information.
Market effects
Minimal; health insurance sector already incorporates Cigna's guidance.
None
None
Counterpoint
If investors believe the guidance is overly conservative, there could be upside potential.
Key entities
- AnalystUBS
Provides rating and price target for Cigna.
- CompanyCigna Group
Subject of the article; health insurer.
